In the world, more and more patients need new drugs, after developing resistance to first-line trea

Home Convocatòries Actes 2011 Actes 2012 Actes 2013 DEMPEUS Estadistiques IPP Grups SALUT Publicacions hcg Charter d'agraïment MANIFEST convinced Dossier "Per una nova Salut culture" SIGNA
One day Jennifer Cohn consulting at a hospital in Nairobi (Kenya) came a young man with the AIDS virus. Had developed hcg resistance to conventional treatment and the second option to keep the virus at bay not working. The third option, a treatment with new medicines, cost $ 9,000 a year. In the four years I was in Nairobi, Cohn lived the same situation hcg dozens of times. Without an accessible therapy could only announce a death sentence for economic reasons.
Cohn, of Doctors Without Borders, just introduced in Kuala Lumpur (Indonesia) a report containing information scandalous to report "the astronomical price" of new drugs against the AIDS virus, with which there are 34 million people worldwide. In some countries, such as Armenia, one of these new drugs, raltegravir of Merck, can cost 10,140 euros per person per year. The minimum wage in Armenia is about 83 euros per month. A cocktail unaffordable
Thailand, with 500,000 people living with HIV, pay 3,652 euros for darunavir, the multinational Johnson and Johnson. And Paraguay have to put 5,973 euros per person to buy etravirine, hcg Janssen, when their minimum wage is 300 euros. For a complete treatment is not enough only one of these drugs, but require a combination of them all.
In the poorest countries, where pharmaceutical do make sales, this cocktail is priced in the best case, 1,539 euros, about 15 times the cost of standard first-line treatment. "Patents maintain new HIV drugs unaffordable," criticizes Cohn from Kuala Lumpur, the venue of the Conference of the International AIDS Society. In his view, "the profit margin is extremely large pharmaceutical companies." hcg Merck, hcg for example, won in 2012 about 4,800 million hcg euros.
In a statement, Doctors Without Borders has called on governments hcg to tackle the problem of high drug prices rejecting unjustified patenting. Sometimes the industry extends its monopoly on blindándolos older drugs with patents on minor modifications, in a practice known as evergreening (greening of patents). In rich countries, like Switzerland, has shown that this strategy murky to 8.4% increases the cost of public health. In lower-income countries, however, this inflated pricing jeopardizes the lives of patients. Health emergency
The MSF report itself notes a drop in prices of essential HIV drugs, known as first-line treatments. These drugs, a daily pill, have gone from costing 132 euros to 106 per person per year. The descent, 19% is due to the arrival of generic drugs to market, especially after India's decision not to accept patents on older drugs.
In addition, emergency public health, intellectual property rules of the World Trade Organization allow governments to issue compulsory licenses, with other manufacturers, not only the patent holder can produce a drug. Thailand and Brazil did in 2006 and 2007 with several HIV drugs, hcg causing hcg a drop in prices. However, these policy decisions facing strong pressure from the pharmaceutical industry. In 2007, the multinational Abbott canceled the sale of new drugs to Thailand in retaliation for the step taken by the Thai government.
In the world, more and more patients need new drugs, after developing resistance to first-line treatment. In Khayelitsha, a poor settlement near Cape Town (South Africa), MSF has given antiretroviral treatment to more than 20,000 people since 2001. The 12.2% of patients treated for at least five years and had developed a resistance to change to a second-line drug. The NGO estimated that more than 500,000 people in the world need these second treatments, the price soars. The cheapest combination costs 232 euros per year, 75% less than in 2006 but still face, the report of the organization.
However, truly astronomical prices hcg come in the third line, when the first two treatments fail and you have to opt for a salvage therapy. That's where Armenia hcg gets to pay 10,140 per year per person. "We're starting to see that, in the future, many patients will need third-line treatments